Biotech & Life Sciences in Continental Europe is run through 8 jurisdictions in the Reuben AI registry: Luxembourg, Germany, France, Netherlands, Spain, Italy, Sweden and Poland. Each carries its own regulator, vehicle wrappers and primary source citations, and Reuben AI scores, documents and reports biotech & life sciences deals on one rubric across all of them.
Investment in therapeutics, diagnostics, medical devices, and life-sciences platforms, structured to withstand extended clinical and regulatory timelines.
Continental European private capital spans Luxembourg RAIF and SCSp structures, French FPCI and SLP vehicles, German Investment KG under the KAGB, Dutch FGR and CV vehicles, Spanish FCR structures, Italian FIA italiani chiusi, Swedish AIFs, and Polish ASI vehicles, all operating under AIFMD.
Luxembourg private funds are typically RAIFs, SIFs or SICAVs wrapped as SCSp partnerships, managed by an authorised or registered AIFM subject to CSSF supervision, with UCITS available for regulated cross-border retail distribution.
German private funds operate under the Kapitalanlagegesetzbuch (KAGB), with managers registered or authorised as Alternative Investment Fund Managers by BaFin.
French private funds commonly take the form of FPCI, SLP or FCPR vehicles, managed by a société de gestion authorised or registered with the AMF.
Dutch private funds commonly use CV or FGR wrappers with the manager licensed or registered as an AIFM under the Wet op het financieel toezicht, supervised by the AFM with prudential oversight from DNB.
Spanish private capital vehicles are typically FCR or SCR entities regulated under Ley 22/2014, with the management company authorised by the CNMV as an SGEIC.
Italian private funds are typically closed-ended FIAs under the Testo Unico della Finanza (D.Lgs. 58/1998), managed by an SGR authorised by Banca d'Italia with conduct oversight by CONSOB.
Swedish private funds commonly use kommanditbolag structures with the manager authorised or registered under Lag (2013:561) om förvaltare av alternativa investeringsfonder, supervised by Finansinspektionen.
Polish private funds are typically ASI vehicles under the Ustawa o funduszach inwestycyjnych, with managers registered as ZASI and reporting AIFMD Annex IV to the KNF.
The investment case for biotech & life sciences does not change by geography. Investment in therapeutics, diagnostics, medical devices, and life-sciences platforms, structured to withstand extended clinical and regulatory timelines.
What changes is the wrapper and the supervision around it. In Continental Europe the vehicles in use are SICAV investment company with variable capital under the Law of 17 December 2010 or the Law of 13 February 2007, Special Limited Partnership (SCSp) under the Law of 10 August 1915, Reserved Alternative Investment Fund (RAIF) under the Law of 23 July 2016, Specialised Investment Fund (SIF) under the Law of 13 February 2007, UCITS Fund under Part I of the Law of 17 December 2010, Investment-Kommanditgesellschaft (Investment KG) under the KAGB, Special AIF (Spezial-AIF) for professional and semi-professional investors, Registered or fully authorised AIFM under the KAGB, Fonds Professionnel de Capital Investissement (FPCI) and Société de Libre Partenariat (SLP), among 27 wrappers in total, supervised by CSSF (Commission de Surveillance du Secteur Financier), BaFin (Bundesanstalt für Finanzdienstleistungsaufsicht), AMF (Autorité des marchés financiers), AFM (Autoriteit Financiële Markten), CNMV (Comisión Nacional del Mercado de Valores) and Banca d'Italia and other national regulators. Continental European private capital spans Luxembourg RAIF and SCSp structures, French FPCI and SLP vehicles, German Investment KG under the KAGB, Dutch FGR and CV vehicles, Spanish FCR structures, Italian FIA italiani chiusi, Swedish AIFs, and Polish ASI vehicles, all operating under AIFMD.
Those differences land in fund operations rather than in the deal thesis: the disclosure a regulator expects, the reporting cadence an LP is used to, the currency a capital account is denominated in (EUR, SEK and PLN), and which documents must exist before a commitment can be drawn. Reuben AI holds those requirements per jurisdiction, so a biotech & life sciences deal is scored on the shared rubric while the jurisdiction-specific checks run alongside it.
A manager holding biotech & life sciences in more than one Continental Europe jurisdiction usually ends up with more than one process: a different checklist per vehicle, a different reporting pack per LP base, and no single ranking of the portfolio. That is the problem the platform removes.
Deals are scored on the biotech & life sciences rubric regardless of where the vehicle sits. Key terms are extracted with a clause-level source reference. Jurisdiction-specific flags are raised against the framework that applies to that vehicle, with the regulator and the primary source recorded on the deal. The investment committee pack and the LP report are generated from that same stored record.
The result is that a biotech & life sciences position in one Continental Europe jurisdiction is directly comparable to a position in another, and to positions in every other asset class the fund holds, without a reconciliation step.
Luxembourg, Germany, France, Netherlands, Spain, Italy, Sweden and Poland. Each is held in the jurisdictional registry with its regulator, common fund structures and primary source citations, all listed on this page.
CSSF (Commission de Surveillance du Secteur Financier), BaFin (Bundesanstalt für Finanzdienstleistungsaufsicht), AMF (Autorité des marchés financiers), AFM (Autoriteit Financiële Markten), CNMV (Comisión Nacional del Mercado de Valores), Banca d'Italia, Finansinspektionen and KNF (Komisja Nadzoru Finansowego). Regulator links and the underlying statutes are cited on this page so any claim can be checked against the primary source.
SICAV investment company with variable capital under the Law of 17 December 2010 or the Law of 13 February 2007, Special Limited Partnership (SCSp) under the Law of 10 August 1915, Reserved Alternative Investment Fund (RAIF) under the Law of 23 July 2016, Specialised Investment Fund (SIF) under the Law of 13 February 2007, UCITS Fund under Part I of the Law of 17 December 2010, Investment-Kommanditgesellschaft (Investment KG) under the KAGB, Special AIF (Spezial-AIF) for professional and semi-professional investors, Registered or fully authorised AIFM under the KAGB, Fonds Professionnel de Capital Investissement (FPCI), Société de Libre Partenariat (SLP), Fonds Commun de Placement à Risques (FCPR) and AMF-authorised or registered management company (société de gestion), plus further wrappers held in the registry. The structure determines the disclosure and reporting requirements the platform applies, not the rubric the deal is scored on.
Biotech in North America
North American private capital is anchored by SEC-supervised managers running Delaware limited partnerships
Biotech in LatAm
Latin American private capital spans Brazilian FIPs under CVM Resolução 175
Biotech in UK & Ireland
UK and Ireland private capital combines English and Scottish limited partnerships under the Limited Partnerships Act 1907 (FCA-regulated managers) with Irish ILP and ICAV structures supervised by the Central Bank of Ireland.
Biotech in APAC
APAC private capital covers Singapore VCCs
Biotech in Global
Reuben AI supports fund structuring
Venture Capital in Continental Europe
Minority equity investment in early- and growth-stage private companies
Private Equity in Continental Europe
Direct equity investment in privately held companies through closed-end funds
Buyout in Continental Europe
Control or majority transactions in mature companies
Growth Equity in Continental Europe
Minority equity in scaled
Private Credit in Continental Europe
Non-bank lending to private companies
Private Debt in Continental Europe
Privately originated debt instruments
Book a walkthrough with our team, or start a free workspace and we'll meet you there. Most institutional teams do both.